Harmony Biosciences Holdings (HRMY) Free Cash Flow (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Free Cash Flow of $27.8 million for Q1 2026, down 77.98% sequentially from $126.0 million in Q4 2025, and down 18.01% YoY from $33.9 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Free Cash Flow (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Free Cash Flow for 8 years, with the latest figure at $27.8 million in Q1 2026.
- Quarterly Free Cash Flow fell 18.01% year-over-year to $27.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $341.8 million (up 54.38% YoY) and the FY2025 annual result came in at $347.9 million, up 59.09% from the prior year.
- Free Cash Flow declined to $27.8 million in Q1 2026 per HRMY's latest filing, from $126.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $126.0 million in Q4 2025 and troughed at $26.7 million in Q4 2022.
- A 5-year average of $56.3 million and a median of $42.6 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow slipped 28.92% in 2022, then surged 186.97% in 2023.
- Over 5 years, Free Cash Flow stood at $26.7 million in 2022, then soared by 186.97% to $76.6 million in 2023, then declined by 1.97% to $75.0 million in 2024, then surged by 67.95% to $126.0 million in 2025, then tumbled by 77.98% to $27.8 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $27.8 million, $126.0 million, and $108.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 92.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.43 Mn |
| Jun 30, 2026 | 92.43 Mn |
| Mar 31, 2026 | 27.76 Mn |
| Mar 31, 2026 | 27.76 Mn |
| Dec 31, 2025 | 126.04 Mn |
| Dec 31, 2025 | 126.04 Mn |
| Sep 30, 2025 | 108.66 Mn |
| Sep 30, 2025 | 108.66 Mn |
| Jun 30, 2025 | 79.32 Mn |
| Jun 30, 2025 | 79.32 Mn |
| Mar 31, 2025 | 33.86 Mn |
| Mar 31, 2025 | 33.86 Mn |
| Dec 31, 2024 | 75.05 Mn |
| Dec 31, 2024 | 75.05 Mn |
| Sep 30, 2024 | 70.50 Mn |
| Sep 30, 2024 | 70.50 Mn |
| Jun 30, 2024 | 41.99 Mn |
| Jun 30, 2024 | 41.99 Mn |
| Mar 31, 2024 | 31.14 Mn |
| Mar 31, 2024 | 31.14 Mn |